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Antiphospholipid syndrome (APS) is characterized by thromboses and neuropsychiatric manifestations possibly linked to brain
inﬂammation. In order to examine the levels of proinﬂammatory and anti-inﬂammatory cytokines in experimental APS (eAPS)
mice brains, we measured the levels of TNF-α,I F N - γ, and IL-10 in brain homogenates (cytosolic fractions) and in brain slices
(secreted level) at 6, 15, and 24 weeks after immunization. We induced eAPS by immunization of Balb/c mice with β2-glycoprotein
I( β2GPI), the major autoantigen in the disease and controls with adjuvant alone. We found increased levels of secreted TNF-α in
eAPS mice for the entire experiment period. Cytosolic and secreted IL-10 and IFN-γ levels in eAPS mice were lower at 6 and 15
weeks and higher at 24 weeks after immunization. The results suggest that brain disease in APS is associated with signiﬁcant and
complex changes in proinﬂammatory and anti-inﬂammatory cytokines.
1.Introduction
The antiphospholipid (Hughes) syndrome (APS) is an
autoimmune disorder, manifested by thromboembolic
events (arterial and venous), recurrent spontaneous abor-
tions, thrombocytopenia, and elevated titers of circulating
antiphospholipid antibodies (aPL)[1].MostaPLareautoan-
tibodies directed against a complex of phospholipids and β2-
glycoprotein I (β2GPI), a major cofactor in the binding of
aPL, causing hypercoagulation and a proinﬂammatory state
[2]. Many neurological manifestations have been described
in the APS, butonly stroke is well established and accepted as
a diagnostic criterion in the disease [3]. Other neurological
complications, which still need to be fully established,
include seizures, ocular disturbances, dementia, migraine,
transverse myelitis, and chorea [4].
A model of experimental APS (eAPS) in mice is induced
by immunization with β2GPI [5]. Previous studies in our
lab found behavioral changes in eAPS mice, which include
hyperactivity/exploratory behavior and cognitive deﬁcits
[6–8]. The CNS manifestation developed over a period of
4-5 months after immunization [9]. The role of aPL in the
pathogenesis of APS still needs to be elucidated. It is possible
that other immune mediators, apart from autoantibodies,
take part in the inﬂammatory and degenerative processes in
the APS brain.
Although APS is considered a B-cell mediated disease
[10], T cells also have an important role in the induction
and regulation of the disease, by secreting cytokines which
modulate the immune response [11]. Cytokines can be
divided into two subgroups: proinﬂammatory cytokines
and anti-inﬂammatory cytokines. The course of many
diseases, including several autoimmune diseases, depends
upon the balance between these two subgroups [12]. Pro-
inﬂammatory cytokines and chemokines have been reported
to have an important role in the development of the clinical
manifestation of APS [11, 13]. Previous clinical reports
have shown increased serum levels of IL-4 and IL-6 in
patients with APS [14, 15]. Another central inﬂammatory
cytokine associated with APS is tissue necrosis factor-α
(TNF-α), levels of whichare known to be elevatedand reﬂect
pathological processes within the endothelial cells [15, 16].2 Autoimmune Diseases
The cytosolic cytokine content of brain homogenate
consists of two parts, one of which is secreted from the
activated immune cells or the activated endothelial cells and
participates in the modulation of the immune response.
The second cytokine fraction is stored within immune and
endothelial cells as a reserve and has less immediate eﬀect
on the immune response. We hypothesized that the secreted
fraction is the one which contributes to development of
APS pathogenesis. Our aim in the present study was to
compare a number of brain inﬂammatory cytokines (TNF-
α,I F N - γ, and IL-10) measured both as cytosolic levels (i.e.,
their concentration in a cytosolic fraction) and as secreted
levels (i.e., their concentration when they secretes from
brain slices). Changes over the course of 6 months were
monitored.
2.MaterialsandMethods
2.1. Mice. Female Balb/C mice, aged 8 weeks, were obtained
from Harlan Laboratories Limited, Israel. The mice were
raised at the Sackler Medical School, Tel Aviv University,
animal facility, under standard conditions, 23 ± 1◦C, 12h
light cycle (7am ± 7pm) with ad libitum access to food and
drink. The Tel Aviv University Animal Welfare Committee
approved all procedures (M-08-053).
2.2. Induction of Experimental APS. The eAPS group (n =
15) was immunized once subcutaneously with 10μg β2GPI
emulsiﬁedincompleteFreund’sadjuvant(CFA).Thecontrol
group (n = 15) was immunized similarly with CFA alone. In
order to monitor changes over time, mice were divided into
threegroups;eachgroupcontained10mice,5fromtheeAPS
group and 5 from the control group. The ﬁrst group was
sacriﬁced 6 weeks after immunization, the second group was
sacriﬁced 15 weeks after immunization, and the third group
was sacriﬁced 24 weeks after immunization.
2.3. Serology Evaluation. Mice were bled by left ventricle
puncture before their brains were perfused and harvested.
The sera were separated by centrifugation (9600×gf o r1 0
m i n u t e s )a n ds t o r e da t– 2 0 ◦C until assayed. The sera were
tested by ELISA for the presence of antibodies to cardiolipin
(β2GPI-dependent) as previously described [10].
2.4. Tissue Preparation. Each mouse, under equithesin anes-
thesia, was perfused through the heart with PBS (pH 7.4)
containing 5U/mL heparin. After perfusion, the brain was
quickly removed and was cut into two halves. One half of the
brain was homogenized using disposable rotor homogenizer
(OMNI-INC) in 10 volumes of radioimmunoprecipitation
assay(RIPA)buﬀer(50mMTris-HCl,150mMNaCl,pH7.4)
supplemented with 1mM ethylenediaminetetraacetic acid
(EDTA), 1mM phenylmethylsulphonyl ﬂuoride (PMSF),
and a protease inhibitor cocktail (Sigma-Aldrich) and was
separated to subcellular fractions detailed below; the second
half of the brain was stored at −70◦C until it was cut serially
into 50μm thick, coronal sections on a cryostat (Leica). The
sections were kept in a cryoprotectant (28% Glycerol, 29%
Ethylene glycol in 0.1M PO4)a t– 2 0 ◦C until assayed.
Weeks after immunization
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Figure 1: Antibodies to cardiolipin (β2GPI-dependent) in eAPS
(black bars) and adjuvant control mice (white bars) sera 6, 15, and
24 weeks after immunization. Results are presented as the mean
absorbance values ± SEM.
2.5. Subcellular Fractionation. All steps were carried at 4◦C.
The homogenate was centrifuged at 2900×g for 20min. The
pellet (nuclear fraction) was resuspended with RIPA buﬀer
containing 1mM EDTA and protease inhibitor cocktail,
whilst the supernatant was centrifuged at 29000×gf o r
45min. The resulting supernatant (cytosol fraction) was
collected and kept at –20◦C until assayed.
2.6.DeterminationofCytokineLevels. Tumor necrosis factor-
alpha (TNF-α), interleukin-10 (IL-10), and interferon-
gamma (IFN-γ) concentrations were measured by speciﬁc
quantitative sandwich ELISA kits (PeproTech Inc.) according
to the manufacturer’s instructions. The cytosolic cytokine
level was measured in the cytosolic fraction of a whole brain
homogenate. In order to measure secreted fraction from the
cells, brain slices were incubated for 2 hours at 37◦C in PBS
(pH 7.4) buﬀer. The supernatant was collected; its protein
concentration was measured by the bicinchoninic acid
(BCA) method, and the concentrations of the cytokines were
measured by the ELISA kits as for the cytosolic fractions.
2.7. Statistical Analysis. Results are expressed as mean values
± standard error of mean (SEM). Cytokine levels were
compared for immunization and time eﬀects between the
appropriate groups by means of a univariate 2-way ANOVA.
Interaction for group × time was also performed. Post hoc
analysiswasperformedbyt-test.Allanalyseswereperformed
by SPSS (Chicago IL). In order to standardize and enable
comparison between various experiments, mean of controls
were calculated as 100%.
3. Results
3.1. Autoantibody Levels. Antibody levels to cardiolipin
(β2GPI-dependent) in the sera are presented in Figure 1.
Six weeks after immunization eAPS mice developed elevatedAutoimmune Diseases 3
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Figure 2: Secreted TNF-α levels of adjuvant mice (black bars) and
eAPS mice (upward diagonal bars) versus cytosolic TNF-α levels of
adjuvant mice (grey bars) and eAPS mice (white bars). The average
of TNF-α level of the adjuvant control group was deﬁned as 100%,
and the results expressed as percentage of control group at the same
time point. Results are presented as the mean ± SEM.
titers of antibodies to cardiolipin. Antibody levels were
signiﬁcantly higher in eAPS compared to control mice
immunized with CFA alone (1.32 ± 0.28 and 0.02 ± 0.01
OD units, resp., P<0.001 by t-test). Fifteen weeks after
immunization, antibody levels in eAPS mice were decreased
but still remained signiﬁcantly higher compared to controls
(0.63 ± 0.04 and 0.06 ± 0.01 OD units, resp., P<0.001 by t-
test). Twenty-four weeks after immunization, antibody levels
in eAPS mice were remained signiﬁcantly higher compared
to controls (0.52 ± 0.11 and 0.06 ± 0.01 OD units, resp.,
P<0.005 by t-test).
3.2. Secreted versus Cytosolic Cytokine Levels
3.2.1. TNF-α Level. Cytosolic and secreted TNF-α levels of
eAPS and control mice are presented in Figure 2.T N F -
α levels were calculated as percentage of control group.
Secreted TNF-α level in the control group remained stable at
6 and 15 weeks (3.7 ± 1.3pg/mL and 3.7 ± 0.3pg/mL, resp.)
and decreased slightly at 24 weeks (2.1 ± 0.8pg/mL). In the
eAPS group, secreted TNF-α level was at its highest level at
6 weeks, while, at 15 weeks, it decreased and remained at
the same level at 24 weeks. As can be seen, secreted TNF-α
levelswerehigherintheeAPSgroupcomparedtothecontrol
group at 6, 15, and 24 weeks. Analysis for the eﬀect of group
and time by univariate 2-way ANOVA revealed a signiﬁcant
eﬀect of group (P = 0.02). There was no signiﬁcant eﬀect
for the interaction group × time (P>0.5) indicating that
the behavior of both groups was similar over time. Post
hoc analysis by t-test revealed signiﬁcant diﬀerence between
groups at 6 and 15 weeks (P<0.05).
Cytosolic TNF-α level in the control group was stable at
6 and 15 weeks (4.2 ± 0.7μg/mL and 4.0 ± 0.8μg/mL, resp.)
and increased at 24 weeks (5.9 ± 1.0μg/mL). In the eAPS
group,cytosolicTNF-αlevelwasatitslowestlevelat6weeks,
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Figure 3: Secreted IL-10 levels of adjuvant mice (black bars) and
eAPS mice (upward diagonal bars) versus cytosolic IL-10 levels of
adjuvant mice (grey bars) and eAPS mice (white bars). The average
of IL-10 level of the adjuvant control group was deﬁned as 100%,
and the results expressed as percentage of control group at the same
time point. Results are presented as the mean ± SEM.
while, at 15 weeks, it was increased and remained at the same
l e v e la t2 4w e e k s .A sc a nb es e e n ,c y t o s o l i cT N F - α levels were
lower in the eAPS group compared to the control group at
6 and 24 weeks, while, at 15 weeks, levels in the eAPS group
and the control group were similar. Analysis for the eﬀects
of group and time by univariate 2-way ANOVA revealed a
nonsigniﬁcant eﬀect of group and time (P<0.1, P = 0.17
resp.). There was no eﬀect for the interaction group × time
(P>0.3).
3.2.2.IL-10Level. CytosolicandsecretedIL-10levelsofeAPS
and control mice are presented in Figure 3. IL-10 levels were
calculated as percentage of control group. Secreted IL-10
level in the control group was at its highest level at 6 weeks
(25.7 ± 1.4pg/mL) and gradually decreased at 15 and 24
weeks (15.7 ± 2.1pg/mL and 9.9 ± 1.7pg/mL, resp.). In
the eAPS group, secreted IL-10 was at its lowest level at 15
weeks; at 6 and 24 weeks, the levels were similar. As can be
seen, secreted IL-10 level in the eAPS group compared to the
control group was lower at 6 and 15 weeks and higher at 24
weeks. Analysis for the eﬀect of group and time by univariate
2-wayANOVArevealedasigniﬁcanteﬀectoftime(P<0.03).
There was a signiﬁcant eﬀect for the interaction of group ×
time (P<0.02) due to the decrease over time in the control
group level.
Cytosolic IL-10 level in the control group was 7.6 ±
0.5μg/mL,11.5 ±1.4μg/mL,and84.0 ±17.4μg/mL,at6,15,
and 24 weeks, respectively. In the eAPS group, cytosolic IL-
10 level decreased to its lowest level at 15 weeks; at 24 weeks,
IL-10 increased to its highest level. Similarly to the secreted
IL-10 level, cytosolic IL-10 level in the eAPS group compared
to the control group was lower at 6 and 15 weeks and
higher at 24 weeks. Analysis for the eﬀect of group and time
by univariate 2-way ANOVA revealed a signiﬁcant eﬀect of
group(P<0.01)andtime(P<0.01).Therewasasigniﬁcant4 Autoimmune Diseases
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Figure 4: Secreted IFN-γ levels of adjuvant mice (black bars) and
eAPS mice (upward diagonal bars) versus cytosolic IFN-γ levels of
adjuvant mice (grey bars) and eAPS mice (white bars). The average
of IFN-γ level of the adjuvant control group was deﬁned as 100%,
and the results expressed as percentage of control group at the same
time point. Results are presented as the mean ± SEM.
eﬀect for the interaction of group × time (P<0.01). Post
hoc analysis by t-test revealed a signiﬁcant eﬀect at 15 and
24 weeks (P<0.05) and a trend toward increased levels of
cytosolic IL-10 in the control group at 6 weeks (P = 0.16).
3.2.3. IFN-γ Level. Cytosolic and secreted IFN-γ levels of
eAPSandcontrolmicearepresentedinFigure 4.IFN-γ levels
were calculated as percentage of control group. Secreted IFN-
γ level in the control group was at its highest level at 6
weeks (9.8 ± 2.1pg/mL), and, at 15 and 24 weeks, the levels
gradually decreased (8.8 ± 0.9pg/mL and 5.0 ± 0.8pg/mL,
resp.). In the eAPS group, secreted IFN-γ level was stable for
the whole period. As can be seen, secreted IFN-γ level in the
eAPS group compared to the control group was lower at 6
and 15 weeks and higher at 24 weeks. Analysis for the eﬀect
of group and time by univariate 2-way ANOVA revealed no
signiﬁcant eﬀect for either group or time (P = 0.19 for
both).Therewasnoeﬀectfortheinteractionofgroup ×time
(P>0.5).
Cytosolic IFN-γ level in the control group was 6.3 ±
0.5μg/mL, 7.5 ± 0.6μg/mL, and 4.5 ± 0.6μg/mL at 6, 15,
and 24 weeks, respectively. In the eAPS group, cytosolic IFN-
γ level was stable at 6 and 15 weeks and increased at 24
weeks. As can be seen, cytosolic IFN-γ level in the eAPS
group compared to the control group was lower at 6 and 15
weeks and higher at 24 weeks. Analysis for the eﬀect of group
and time by univariate 2-way ANOVA revealed no signiﬁcant
eﬀect for either group or time (P>0.3o rP>0.5, resp.).
There was a signiﬁcant eﬀect for the interaction of group ×
time (P<0.05).
4. Discussion
Inthepresentstudy,wemeasuredinﬂammatorysecretedand
cytosolic cytokines levels in eAPS and adjuvant mice brains
during a 24-week period. Secreted TNF-α level was higher in
eAPS mice compared to adjuvant mice for the whole period.
Higher secreted TNF-α levels in eAPS mice are in line with
previous studies that found higher TNF-α levels in eAPS
mice and APS patients [15, 16]. On the other hand, cytosolic
TNF-α levels were somewhat lower in eAPS mice compared
to adjuvant mice at 6 and 24 weeks and similar at 15 weeks
after immunization.
Explanation for the lower cytosolic TNF-α level in eAPS
miceat6weeksafterimmunizationmightbeahighsecretion
of TNF-α during the pathological processes, resulting in
emptying thecellreserves. As mentioned above, the cytosolic
cytokine content of brain homogenate consists of a stored
fraction and a secreted fraction. The ﬁrst fraction is stored
within immune and endothelial cells as a reserve and has
less immediate eﬀect on the immune response. The second
fraction is secreted from the activated immune cells or the
activatedendothelial cellsand participates in the modulation
the immune response. We hypothesize the levels of secreted
cytokines reﬂect, as closely as possible, the condition of
cytokines levels in vivo, since the tissue and the cells
structures remain unbroken. We have previously measured
TNF-α level in mice whole brain homogenate. TNF-α level
was found to be signiﬁcantly higher in eAPS mice compared
to adjuvant mice [16]. We hypothesize that the TNF-α level
measured in mice whole brain homogenate is similar to the
secreted TNF-α level rather than to the cytosolic TNF-α level
measured in mice cytosolic brain fraction. In comparison
to the clean cytosolic fraction, whole brain homogenate
contains other components which may mask the cytokine
fraction stored within the immune and endothelial cells.
Other important cytokines in the development of the
inﬂammatory process are IL-10 and IFN-γ. Cytosolic and
secreted IL-10 and IFN-γ levels in eAPS mice were lower at
6 and 15 weeks and higher at 24 weeks after immunization
compared to adjuvant mice. The low stable secreted and
cytosolicIFN-γ levelsin theeAPSgroupisin agreementwith
previous study which showed a rise in IFN-γ in eAPS mice
after treatment with anti-idiotypic monoclonal antibody
(MoAb) [17]. IFN-γ is a proinﬂammatory cytokine and has
a major role in the inﬂammatory process. Low secreted and
cytosolic IFN-γ levels in eAPS mice might be a result of
upegulation of other cytokines which inhibit its production.
Proinﬂammatory cytokines have an important role in reg-
ulation of haemostatic balance in both physiological and
pathologicstates.TNF-αinﬂuencesendothelialcellsfunction
by upregulating tissue factor (TF) levels [18, 19]. High levels
of TF trigger endothelial cells to change their antithrombotic
propertiesintoprocoagulantstate.Besideitsabilitytoinduce
procoagulant activity, TNF-α also inhibits the thrombomod-
ulin/protein C anticoagulation pathway and aﬀects ﬁbri-
nolysis by upregulating both urokinase-type plasminogen
activatorandplasminogenactivatorinhibitor-1(PAI-1)[20].
While TNF-α contributes to the inﬂammatory process,
IL-10 has an important role in modulating the inﬂamma-
tory response and autoimmune disease. Impairment of the
balance between the inﬂammatory process and the anti-
inﬂammatory response may lead to disproportionate pathol-
ogy or immunosuppression. Initially, IL-10 was consideredAutoimmune Diseases 5
as typical Th2 cytokine. It was identiﬁed as a product of
activated Th2 cells. Recent studies have shown that IL-10 is
also produced by Th1, Th0, regulatory T (Tr1) cells, and in
mice also by activated macrophages and B cells [21]. IL-10
downregulates the inﬂammatory response by blocking the
production of a number of cytokines, including IL-2, IFN-
γ,a n dT N F - α [22]. Therefore, reduced IL-10 levels in eAPS
mice may down modulate the immunosuppressive eﬀects,
resulting in a proinﬂammatory process. In addition, low IL-
10 levels enable TNF-α unregulated production, resulting in
procoagulant state. Moreover, during the B-cell activation,
IL-10 delivers negative signals that promote the apoptosis of
B cells [23]. Decreased IL-10 levels can be associated with
lymphocyteactivation,whichleadstothecontinuationofthe
autoimmune response. At 24 weeks, both total and secreted
IL-10 levels in eAPS mice increased. This is compatible with
an anti-inﬂammatory stage of disease occurring in conjunc-
tion with the drop in the levels of antibodies and TNF-α.
Explanation for the increased IL-10 levels might be their
positive stimulation on B cells. IL-10 has a biphasic eﬀect
on B cells. On activated B cells, IL-10 promotes both their
proliferationanddiﬀerentiationintoantibodysecretingcells.
The importance of immune mediators in APS was
demonstrated in previous studies. Several studies in murine
model of APS showed that in pregnancy loss, some of the
damage is caused by aPL-induced complement activation
[24, 25]. Heparin, an anticoagulant has long been known to
inhibitcomplementactivity[26,27].Girardietal.foundthat
heparin, but neither fondaparinux nor hirudin, inhibited
the generation of complement split products and protected
mice from fetal loss caused by aPL antibodies [28]. Some
CNS manifestations of APS are caused by inﬂammation,
cytokines or antibody-mediated tissue damage, and, there-
fore, antithrombotic therapy in APS is not suﬃcient.
The results suggest that course of the inﬂammatory
process in eAPS depends upon the balance between proin-
ﬂammatory and anti-inﬂammatory cytokines. Today, the
accepted treatment for APS is antithrombotic therapy. Our
results in line with previous cytokine studies may indicate
a new therapeutic approach to APS. Drugs against proin-
ﬂammatory cytokines may rebalance the cytokines levels and
moderate the inﬂammatory response.
Acknowledgment
This research was supported by The Israel Science Founda-
tion (Grant no. 917/08).
References
[1] J. H. Rand, “Molecular pathogenesis of the antiphospholipid
syndrome,” Circulation Research, vol. 90, no. 1, pp. 29–37,
2002.
[2] R. A. S. Roubey, C. W. Pratt, J. P. Buyon, and J. B. Winﬁeld,
“Lupus anticoagulant activity of autoimmune antiphospho-
lipid antibodies is dependent upon β2-glycoprotein I,” Journal
of Clinical Investigation, vol. 90, no. 3, pp. 1100–1104, 1992.
[3] R.L.Brey,J.Chapman,S.R.Levineetal.,“Strokeandtheanti-
phospholipid syndrome: consensus meeting Taormina 2002,”
Lupus, vol. 12, no. 7, pp. 508–513, 2003.
[4] G. Ruiz-Irastorza, M. A. Khamashta, and G. R. V. Hughes,
“Hughes syndrome crosses boundaries,” Autoimmunity Re-
views, vol. 1, no. 1-2, pp. 43–48, 2002.
[ 5 ]A .E .G h a r a v i ,L .R .S a m m a r i t a n o ,J .W e n ,a n dK .B .E l k o n ,
“Induction of antiphospholipid autoantibodies by immuniza-
tion with β2 glycoprotein I (apolipoprotein H),” Journal of
Clinical Investigation, vol. 90, no. 3, pp. 1105–1109, 1992.
[6] A. Katzav, Y. Litvinjuk, C. G. Pick et al., “Genetic and immu-
nological factors interact in a mouse model of CNS antiphos-
pholipid syndrome,” Behavioural Brain Research, vol. 169, no.
2, pp. 289–293, 2006.
[ 7 ]A .K a t z a v ,C .G .P i c k ,A .D .K o r c z y ne ta l . ,“ H y p e r a c t i v i t yi na
mouse model of the antiphospholipid syndrome,” Lupus, vol.
10, no. 7, pp. 496–499, 2001.
[8] Y.Shoenfeld,A.Nahum,A.D.Korczynetal.,“Neuronal-bind-
ing antibodies from patients with antiphospholipid syndrome
induce cognitive deﬁcits following intrathecal passive trans-
fer,” Lupus, vol. 12, no. 6, pp. 436–442, 2003.
[9] S. Shrot, A. Katzav, A. D. Korczyn et al., “Behavioral and cog-
nitive deﬁcits occur only after prolonged exposure of mice to
antiphospholipid antibodies,” Lupus, vol. 11, no. 11, pp. 736–
743, 2002.
[10] R. Bakimer, P. Fishman, M. Blank, B. Sredni, M. Djaldetti,
and Y. Shoenfeld, “Induction of primary antiphospholipid
syndrome in mice by immunization with a human mon-
oclonal anticardiolipin antibody (H-3),” Journal of Clinical
Investigation, vol. 89, no. 5, pp. 1558–1563, 1992.
[11] P. Fishman, R. Bakimer, M. Blank, D. Sredni, M.Djaldetti, and
Y. Shoenfeld, “The putative role of cytokines in the induction
of primary anti-phospholipid syndrome in mice,” Clinical and
Experimental Immunology, vol. 90, no. 2, pp. 266–270, 1992.
[12] T. R. Mosmann and S. Sad, “The expanding universe of T-cell
subsets: Th1, Th2 and more,” Immunology Today, vol. 17, no.
3, pp. 138–146, 1996.
[ 1 3 ]M .K a r a k a n t z a ,G .L .T h e o d o r o u ,N .M e i m a r i se ta l . ,“ T y p e1
andtype2cytokine-producingCD4+andCD8+Tcellsinpri-
mary antiphospholipid syndrome,” Annals of Hematology, vol.
83, no. 11, pp. 704–711, 2004.
[14] P. Soltesz, H. Der, K. Veres et al., “Immunological features
of primary anti-phospholipid syndrome in connection with
endothelial dysfunction,” Rheumatology, vol. 47, no. 11, pp.
1628–1634, 2008.
[15] R. Forastiero, M. Martinuzzo, and L. O. Carreras, “Imbalance
towards Th2-type response in patients with deﬁnite primary
antiphospholipid syndrome,” Thrombosis and Haemostasis,
vol. 86, no. 3, pp. 934–935, 2001.
[16] D. Tanne, A. Katzav, O. Beilin et al., “Interaction of inﬂamma-
tion,thrombosis,aspirinandenoxaparininCNSexperimental
antiphospholipid syndrome,” Neurobiology of Disease, vol. 30,
no. 1, pp. 56–64, 2008.
[17] I. Krause, M. Blank, Y. Levi, T. Koike, V. Barak, and Y. Shoen-
feld,“Anti-idiotypeimmunomodulationofexperimentalanti-
phospholipid syndrome via eﬀect on Th1/Th2 expression,”
Clinical and Experimental Immunology, vol. 117, no. 1, pp.
190–197, 1999.
[18] E. Napoleone, A. Di Santo, and R. Lorenzet, “Monocytes up-
regulate endothelial cell expression of tissue factor: a role for
cell-cell contact and cross-talk,” Blood, vol. 89, no. 2, pp. 541–
549, 1997.
[ 1 9 ]M .P .B e v i l a c q u a ,J .S .P o b e r ,G .R .M a j e a u ,W .F i e r s ,R .S .
Cotran, and M. A. Gimbrone Jr., “Recombinant tumor necro-
sis factor induces procoagulant activity in cultured human
vascular endothelium: characterization and comparison with
theactionsofinterleukin1,”ProceedingsoftheNationalAcade-6 Autoimmune Diseases
my of Sciences of the United States of America, vol. 83, no. 12,
pp. 4533–4537, 1986.
[20] G. Grignani and A. Maiolo, “Cytokines and hemostasis,”
Haematologica, vol. 85, no. 9, pp. 967–972, 2000.
[21] H. Groux and F. Cottrez, “The complex role of interleukin-10
in autoimmunity,” Journal of Autoimmunity,v o l .2 0 ,n o .4 ,p p .
281–285, 2003.
[22] H. Yssel, R. D. W. Malefyt, M. G. Roncarolo et al., “IL-10 is
produced by subsets of human CD4+ T cell clones and pe-
ripheral blood T cells,” Journal of Immunology, vol. 149, no. 7,
pp. 2378–2384, 1992.
[23] K. Itoh and S. Hirohata, “The role of IL-10 in human B
cell activation, proliferation, and diﬀerentiation,” Journal of
Immunology, vol. 154, no. 9, pp. 4341–4350, 1995.
[24] G. Girardi, J. Berman, P. Redecha et al., “Complement C5a
receptorsandneutrophilsmediatefetalinjuryintheantiphos-
pholipid syndrome,” Journal of Clinical Investigation, vol. 112,
no. 11, pp. 1644–1654, 2003.
[25] V. Michael Holers, G. Girardi, L. Mo et al., “Complement C3
activation is required for antiphospholipid antibody-induced
fetalloss,”JournalofExperimentalMedicine,vol.195,no.2,pp.
211–220, 2002.
[26] E. Cacciola and S. Cordaro, “Anticomplement power of
heparin,” Bollettino, Societa Italiana Biologia Sperimentale, vol.
33, no. 7, pp. 984–985, 1957.
[ 2 7 ]M .D .K a z a t c h k i n e ,D .T .F e a r o n ,D .D .M e t c a l f e ,R .D .R o -
senberg, and K. F. Austen, “Structural determinants of the
capacity of heparin to inhibit the formation of the human
ampliﬁcation C3 convertase,” Journal of Clinical Investigation,
vol. 67, no. 1, pp. 223–228, 1981.
[28] G. Girardi, P. Redecha, and J. E. Salmon, “Heparin prevents
antiphospholipid antibody-induced fetal loss by inhibiting
complement activation,” Nature Medicine, vol. 10, no. 11, pp.
1222–1226, 2004.